west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "增生细胞核抗原" 2 results
  • PCNA expression in RPE cells and inhibition of antisense oligonucleotides encoding PCNA mRNA to gene expression and proliferation of RPE cells

    Objective To investigate proliferating cell nuclear antigen (PCNA) gene expression in retinal pigment epithelium (RPE) cells and inhibition of antisense oligonucleotides(AS-OND) encoding PCNA mRNA to gene expression and proliferation of RPE cells, so as to search for new genetic therapy way for pro1iferative vitreoretinopathy (PVR). Methods (1) Rabbit RPE cells cultured in vitro were detected for PCNA expression by streptoavidin-biotin-enzyme complex (SABC) immunohistochemistry at several times. (2) The liposome-mediated synthetic antisense oligodeoxynucleotides (AS-ODN) and sense oligodeoxynucleotides (S-ODN) encoding PCNA were delivered to the RPE cells at different concentrations, then PCNA expresstion were detected by immunohistochemistry. (3) Exposed to different concentrations of AS-ODN and S-ODN, growth activity and suppressive rate of RPE cells were measured by methyl thiazolyl tetrazolium (MTT) methods. Results (1) PCNA were expressed in RPE cells, culmination in 48 hours of culture. (2) PCNA expression were markedly suppressed in the RPE cells treated with 0.28 and 1.12 μmol/L PCNA AS-ODN. (3) 0.28 μmol/L and 1.12 μmol/L PCNA AS-ODN significantly inhibited proliferative activity of RPE cells in a dose-dependent manner, the arrest rates of cellular growth reached 53% and 81% respectively. Conclusion AS-ODN complementary to PCNA mRNA at some concentration can sequence-specifically suppress PCNA expression in RPE cells and cellular proliferative activity, and show potential application to further experimental study for PVR genetic medication. (Chin J Ocul Fundus Dis, 2002, 18: 231-233)

    Release date:2016-09-02 06:01 Export PDF Favorites Scan
  • TOPⅡ联合Ki-67和p53表达对局部晚期乳腺癌化疗敏感性的预测分析

    目的探讨TOPⅡ联合p53和Ki-67的表达对局部晚期乳腺癌化疗敏感性的预测价值。 方法采用免疫组化方法检测90例乳腺癌患者不同分子分型的TOPⅡ、p53和Ki-67的表达状况,比较不同TOPⅡ、p53及Ki-67表达状况患者接受新辅助化疗的疗效差异。 结果Ki-67表达阳性率在HER2过表达型、Basal-like型、腺腔A型和腺腔B型之间的差异具有统计学意义(χ2=38.877,P=0.000),其中HER2过表达型和Basal-like型高于腺腔A型和腺腔B型;TOPⅡ及p53的表达表达阳性率在4种分子分型间的差异无统计学意义(χ2=7.105,P=0.069;χ2=7.105,P=0.069)。TOPⅡ和Ki-67表达阳性者的新辅助化疗疗效优于表达阴性者χ2=18.28,P=0.000;χ2=6.64,P=0.009;而p53的表达状况与新辅助化疗的敏感性无关。 结论HER2过表达型和Basal-like型乳腺癌患者对新辅助化疗敏感,疗效好;TOPⅡ表达阳性并Ki-67表达阳性可作为乳腺癌临床化疗患者敏感性生物学指标。

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content